Acute Phase Protein α1-Acid Glycoprotein Interacts with Plasminogen Activator Inhibitor Type 1 and Stabilizes Its Inhibitory Activity

Abstract

␣ 1 -Acid glycoprotein, one of the major acute phase proteins, was found to interact with plasminogen activator inhibitor type 1 (PAI-1) and to stabilize its inhibitory activity toward plasminogen activators. This conclusion is based on the following observations: (a) ␣ 1 -acid glycoprotein was identified to bind PAI-1 by a yeast two-hybrid system. Three of 10 positive clones identified by this method to interact with PAI-1 contained almost the entire sequence of ␣ 1 -acid glycoprotein; (b) this protein formed complexes with PAI-1 that could be immunoprecipitated from both the incubation mixtures and blood plasma by specific antibodies to either PAI-1 or ␣ 1 -acid glycoprotein. Such complexes could be also detected by a solid phase binding assay; and (c) the real-time bimolecular interactions monitored by surface plasmon resonance indicated that the complex of ␣ 1 -acid glycoprotein with PAI-1 is less stable than that formed by vitronectin with PAI-1, but in both cases, the apparent K D values were in the range of strong interactions (4.51 ؉ 1.33 and 0.58 ؉ 0.07 nM, respectively). The on rate for binding of PAI-1 to ␣ 1 -glycoprotein or vitronectin differed by 2-fold, indicating much faster complex formation by vitronectin than by ␣ 1 -acid glycoprotein. On the other hand, dissociation of PAI-1 bound to vitronectin was much slower than that from the ␣ 1 -acid glycoprotein, as indicated by 4-fold lower k off values. Furthermore, the PAI-1 activity toward urokinase-type plasminogen activator and tissue-type plasminogen activator was significantly prolonged in the presence of ␣ 1 -acid glycoprotein. These observations suggest that the complex of PAI-1 with ␣ 1 -acid glycoprotein can play a role as an alternative reservoir of the physiologically active form of the inhibitor, particularly during inflammation or other acute phase reactions.

A meta-analysis of genome-wide association studies identifies ORM1 as a novel gene controlling thrombin generation potential

“…59 One could speculate that a-1-AGP delays thrombin generation by playing the same role with other coagulation inhibitors belonging to the serpin family. Conversely, a-1-AGP has been observed to shorten aPTT 60 and to contribute to the cellular initiation of coagulation by inducing monocyte expression of TF.…”

Mast Cell–Derived Exosomes Activate Endothelial Cells to Secrete Plasminogen Activator Inhibitor Type 1

“…There was also a significant induction of ␣1-acid glycoprotein mRNA, which we recently described to form a complex with active PAI-1 and stabilize its activity. 23 The stimulating effect of exosomes on PAI-1 synthesis was further evidenced by measuring the amount of PAI-1 released to culture media from these cells, as determined by enzyme-linked immunosorbent assay (Figure 2A). To determine the molecular level at which PAI-1 expression can be regulated, we used a transient transfection approach to ask if exosome components can influence the transcription of the PAI-1 promoter.…”

α 1-acid glycoprotein inhibits lipogenesis in neonatal swine adipose tissue

“…(Boncela et al, 2001); however, in that study AGP did not interfere with PAI-1 activity. As previously mentioned, serum AGP concentrations increase during late gestation in the pig and are highest at birth (Lampreave and Piñeiro, 1992), then rapidly decline postnatally Heegaard et al, 2013).…”